Aptinyx Inc reported $100.16M in Cash and Equivalent for its first fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Cash And Equivalent Change
Acadia Pharmaceuticals ACAD:US $ 204.92M 57.48M
Acorda Therapeutics ACOR:US $ 31.87M 13.76M
Biogen BIIB:US $ 1749.3M 512.1M
Cara Therapeutics CARA:US $ 21.36M 7.91M
Daiichi Sankyo 4568:JP Y 662477M 85182M
Eli Lilly And LLY:US $ 2459.2M 1359.3M
Halozyme Therapeutics HALO:US $ 117.84M 0.88M
Intra Cellular Therapies ITCI:US $ 129.29M 36.93M
IONIS PHARMACEUT IONS:US $ 542.51M 326.68M
Marinus Pharmaceuticals MRNS:US $ 126.32M 3.39M
Neurocrine Biosciences NBIX:US $ 270.2M 70.6M
Novartis NOVN:VX SF 13852M 1445M
Ultragenyx Pharmaceutical RARE:US $ 153.99M 153.6M
Vertex Pharmaceuticals VRTX:US $ 7600.1M 805.1M